

ADSTILADRIN[®] and Medicare

ADSTILADRIN[®]
(nadofaragene firadenovec-vncg)
suspension, for intravesical use / 3 x 10¹¹ viral particles/mL

Understanding Part B coverage and reimbursement

- **Medicare Part B covers** drugs administered by infusion or injection in physician offices and hospital outpatient departments
- **Drugs covered under Part B** must be reasonable and necessary for the diagnosis or treatment of an illness or injury
- **Coverage can depend on multiple factors**, including patient diagnosis, type of drug, route of administration, and administration setting
- In the absence of a product's average selling price at launch, **Medicare reimbursement for products under Part B is wholesale acquisition cost + 3%**



Scan the
QR code to
learn more
about Part B
reimbursement

Reference: Medicare Payment Advisory Commission (MedPAC). Part B drugs payment systems. Accessed August 10, 2023. https://www.medpac.gov/wp-content/uploads/2021/11/MedPAC_Payment_Basics_22_PartB_FINAL_SEC.pdf

Ferring and the Ferring Pharmaceuticals logo are registered trademarks of Ferring B.V.
ADSTILADRIN is a registered trademark of Ferring B.V.
© 2023 Ferring B.V. All rights reserved. US-ADST-2300214 v1 08/23

FERRING
PHARMACEUTICALS

The logo icon consists of a central point with several arrows radiating outwards. The arrows are colored in shades of blue and yellow, with the top-right arrow being a distinct yellow.

ADSTILADRIN[®]
(nadofaragene firadenovec-vncg)
suspension, for intravesical use / 3×10^{11} viral particles/mL